Literature DB >> 8720604

Elevated serum levels of macrophage-derived cytokines precede and accompany the onset of IDDM.

M J Hussain1, M Peakman, H Gallati, S S Lo, M Hawa, G C Viberti, P J Watkins, R D Leslie, D Vergani.   

Abstract

To determine whether cytokines could have a role in the development of insulin-dependent diabetes mellitus (IDDM), we measured serum levels of cytokines derived from T helper 1 (interleukin-2 and interferon-gamma), T helper 2 (interleukin-4 and interleukin-10) lymphocytes and macrophages (tumour necrosis factor-alpha, interleukin-1 alpha and interleukin-1 beta) in patients before and after the onset of IDDM. Recently diagnosed IDDM patients had significantly higher levels of interleukin-2, interferon-gamma, tumour necrosis factor-alpha and interleukin-1 alpha than patients with either long-standing IDDM, non-insulin-dependent diabetes (NIDDM), Graves' disease, or control subjects (p < 0.05 for all). Compared with control subjects, patients with long-standing IDDM and those with NIDDM had higher interleukin-2 and tumour necrosis factor-alpha levels (p < 0.01 for all). Interleukin-4 and interleukin-10 were detectable in sera of patients with Graves' disease only, while interleukin-1 beta was not detectable in the serum of any control or test subject. To investigate whether high cytokine levels precede the onset of IDDM, we studied 28 non-diabetic identical co-twins of patients with IDDM, followed-up prospectively for up to 6 years after the diagnosis of the index. Levels of tumour necrosis factor-alpha and interleukin-1 alpha were elevated above the normal range more frequently in the eight twins who developed diabetes than in those 20 who did not (p < 0.005). Analysis of T helper 1 and T helper 2 profiles of the twin groups did not reveal a clear difference between prediabetic twins and twins remaining non-diabetic. These results support the notion that T helper 1 lymphocytes may play a role in the development of IDDM. This is associated with release of macrophage-derived cytokines, which is also a feature of the prediabetic period. The lack of evidence of a dominant T helper 1 profile of cytokine release before diabetes onset suggests that additional events, activating this arm of the cellular immune response, are required in the immediate prediabetic period.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8720604     DOI: 10.1007/BF00400414

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  48 in total

1.  Human TH1 and TH2 subsets: doubt no more.

Authors:  S Romagnani
Journal:  Immunol Today       Date:  1991-08

2.  Pathologic anatomy of the pancreas in juvenile diabetes mellitus.

Authors:  W Gepts
Journal:  Diabetes       Date:  1965-10       Impact factor: 9.461

3.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

Review 4.  Aetiology of insulin-dependent diabetes.

Authors:  R D Leslie; N R Lazarus; D Vergani
Journal:  Br Med Bull       Date:  1989-01       Impact factor: 4.291

5.  Human tumor necrosis factor potentiates human interleukin 1-mediated rat pancreatic beta-cell cytotoxicity.

Authors:  T Mandrup-Poulsen; K Bendtzen; C A Dinarello; J Nerup
Journal:  J Immunol       Date:  1987-12-15       Impact factor: 5.422

6.  Antibodies to GAD and tryptic fragments of islet 64K antigen as distinct markers for development of IDDM. Studies with identical twins.

Authors:  M R Christie; R Y Tun; S S Lo; D Cassidy; T J Brown; J Hollands; M Shattock; G F Bottazzo; R D Leslie
Journal:  Diabetes       Date:  1992-07       Impact factor: 9.461

7.  Cytokines in sera from insulin-dependent diabetic patients at diagnosis.

Authors:  M G Cavallo; P Pozzilli; C Bird; M Wadhwa; A Meager; N Visalli; A J Gearing; D Andreani; R Thorpe
Journal:  Clin Exp Immunol       Date:  1991-11       Impact factor: 4.330

Review 8.  Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM. Therapeutic intervention by immunostimulation?

Authors:  A Rabinovitch
Journal:  Diabetes       Date:  1994-05       Impact factor: 9.461

9.  Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes.

Authors:  D L Kaufman; M Clare-Salzler; J Tian; T Forsthuber; G S Ting; P Robinson; M A Atkinson; E E Sercarz; A J Tobin; P V Lehmann
Journal:  Nature       Date:  1993-11-04       Impact factor: 49.962

10.  Evidence that the T cell repertoire of normal rats contains cells with the potential to cause diabetes. Characterization of the CD4+ T cell subset that inhibits this autoimmune potential.

Authors:  D Fowell; D Mason
Journal:  J Exp Med       Date:  1993-03-01       Impact factor: 14.307

View more
  47 in total

Review 1.  Type I (insulin-dependent) diabetes is a Th1- and Th2-mediated autoimmune disease.

Authors:  S T Azar; H Tamim; H N Beyhum; M Z Habbal; W Y Almawi
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

2.  Protective effect of secoisolariciresinol diglucoside against streptozotocin-induced diabetes and its mechanism.

Authors:  K Prasad; S V Mantha; A D Muir; N D Westcott
Journal:  Mol Cell Biochem       Date:  2000-03       Impact factor: 3.396

Review 3.  Role of cytokines in the pathogenesis of autoimmune diabetes mellitus.

Authors:  Alex Rabinovitch; Wilma L Suarez-Pinzon
Journal:  Rev Endocr Metab Disord       Date:  2003-09       Impact factor: 6.514

4.  Clinical validation of a link between TNF-alpha and the glycosylation enzyme core 2 GlcNAc-T and the relationship of this link to diabetic retinopathy.

Authors:  B M Ben-Mahmud; W H Chan; R M Abdulahad; A Datti; A Orlacchio; E M Kohner; R Chibber
Journal:  Diabetologia       Date:  2006-07-11       Impact factor: 10.122

Review 5.  Inflammation: therapeutic targets for diabetic neuropathy.

Authors:  Jiyin Zhou; Shiwen Zhou
Journal:  Mol Neurobiol       Date:  2013-08-30       Impact factor: 5.590

Review 6.  Type 1 diabetes therapy beyond T cell targeting: monocytes, B cells, and innate lymphocytes.

Authors:  F Susan Wong; Li Wen
Journal:  Rev Diabet Stud       Date:  2012-12-28

7.  Perioperative cytokine release during coronary artery bypass grafting in patients of different ages.

Authors:  A Roth-Isigkeit; J Schwarzenberger; T v Borstel; H Gehring; E Ocklitz; K Wagner; P Schmucker; M Seyfarth
Journal:  Clin Exp Immunol       Date:  1998-10       Impact factor: 4.330

8.  Immune profiling by multiple gene expression analysis in patients at-risk and with type 1 diabetes.

Authors:  Dongmei Han; Carlos A Leyva; Della Matheson; Davide Mineo; Shari Messinger; Bonnie B Blomberg; Ana Hernandez; Luigi F Meneghini; Gloria Allende; Jay S Skyler; Rodolfo Alejandro; Alberto Pugliese; Norma S Kenyon
Journal:  Clin Immunol       Date:  2011-02-24       Impact factor: 3.969

Review 9.  The role of interleukin-1 in the pathogenesis of IDDM.

Authors:  T Mandrup-Poulsen
Journal:  Diabetologia       Date:  1996-09       Impact factor: 10.122

10.  Identification of a novel type 1 diabetes susceptibility gene, T-bet.

Authors:  Yuka Sasaki; Kenji Ihara; Nobuo Matsuura; Hitoshi Kohno; Seiho Nagafuchi; Ryuichi Kuromaru; Koichi Kusuhara; Ryu Takeya; Timothy Hoey; Hideki Sumimoto; Toshiro Hara
Journal:  Hum Genet       Date:  2004-07-06       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.